tirzepatide swiss chems (LY3298176) sodium | GIP/GLP-1 Receptor Agonist | CAS 2023788-19-2 (free base) Zepbound® Tirzepatide Weight Loss Program
Description
They need to know about this event to determine if you should continue the medication
The practical recommendation is the same regardless of starting weight: follow the standard titration schedule, adjust based on tolerance, and let your response guide the maintenance dose
So far, most research has looked at women with PCOS, diabetes, or obesity
Valastro B, Cossette J, Lavoie N, Gagnon S, Trudeau F, Massicotte G
Specifically, while semaglutide users might see a weight reduction of roughly 10% to 15% of their body weight, tirzepatide users in similar trials have reached 20% or more
